SP Potential, page-67

There wasn't any mention of a corporate mandate to CPS/Forrest in the prospectus so it would seem that this may be correct Duthy has decided to take options in lieu of payment which as you say can only be a positive concept.

He has a pretty impressive wrap sheet anyway, I would take a $1,6bn takeover no problems! That was an opportunistic takeover as well.

Prior to establishing Nemean, Tom was the Global Head of Investor Relations & Corporate Development at Sirtex Medical Limited (ASX:SRX) and a member of the Senior Leadership Team. Sirtex is a global medical device player focused on the sale and development of innovative interventional oncology products and was an S&P/ASX 200 Company (also a Top 100 Company from 2015-2017) prior to it being sold. In financial year 2018, the Company recorded revenues of $219 million, an underlying Net Profit After Tax of $41.5 million and operating cash flows of $56.0 million.

In January 2018, it was announced that Sirtex was to be acquired by Varian Medical Systems (NYSE:VAR) for A$1.6 billion. In May 2018, a consortium led by CDH Investments, a China-based alternative asset manager with over US$20 billion under management, announced a superior takeover proposal for Sirtex, valuing the company at A$1.9 billion. The transaction was successfully completed in September 2018. This corporate deal represented the largest ever medical device transaction in Australia by value and was a Top Ten Med Tech M&A deal globally over the previous 12 months. The exit price of $33.60 per share represented a ten year average annual return of over 27% for investors.